Fresno CA 肺癌临床试验
7项针对 肺癌的研究正在 Fresno及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- Kaiser Permanente-Fresno, Fresno
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
招募中3 期
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- Kaiser Permanente-Fresno, Fresno
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Kaiser Permanente Fresno Orchard Plaza, Fresno
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Kaiser Permanente Fresno Orchard Plaza, Fresno
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Kaiser Permanente-Fresno, Fresno
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Kaiser Permanente Fresno Orchard Plaza, Fresno
- Kaiser Permanente-Fresno, Fresno
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
招募中
- VA Medical Center, Fresno, Fresno
其他城市的 肺癌试验
- Houston, TX78 项研究
- Boston, MA62 项研究
- New York City, NY60 项研究
- Los Angeles, CA45 项研究
- Arlington, VA41 项研究
- Washington, DC41 项研究
- Chicago, IL41 项研究
- Baltimore, MD40 项研究
- Nashville, TN40 项研究
- St. Louis, MO39 项研究
- Columbus, OH37 项研究
- Philadelphia, PA36 项研究
Fresno的其他研究
- 非小细胞肺癌7 项研究
- 乳腺癌6 项研究
- 呼吸窘迫综合征6 项研究
- 急性髓系白血病5 项研究
- 偏头痛5 项研究
- 脂肪性肝病5 项研究
- 前列腺癌5 项研究
- 卵巢癌4 项研究
- 急性肺损伤4 项研究
- 癌症（所有类型）4 项研究
- 伯基特淋巴瘤4 项研究
- 骨髓增生异常综合征3 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。